OMNIPAQUE 300 mg I/ml soluzione iniettabile

DRUG4 trials

Sponsors

Mario Negri Institute For Pharmacological Research IRCCS, Istituto Di Ricerche Farmacologiche Mario Negri

Conditions

Hyyperkalemia in CKD stage IIIB to V patientsIdiopathic Nephrotic SyndromeMembranous nephropathyPrimary Membranous Nephropathy

Phase 2

Rescue Therapy with the Human Anti-CD38 Antibody MOR202 (felzartamab) in Patients with Membranous Nephropathy who Failed Anti-CD20 Target Therapy (MONET study)

CompletedCTIS2024-513744-28-00

Istituto Di Ricerche Farmacologiche Mario NegriMembranous nephropathy

Start: 2021-10-22End: 2025-02-21Target: 10Updated: 2024-09-25

Obinutuzumab for primary membranous nephropathy: a pilot study in patients with rituximab-resistant or rituximab-dependent nephrotic syndrome and in patients intolerant to rituximab (the ORION study)

Active, not recruitingCTIS2024-515857-93-00

Istituto Di Ricerche Farmacologiche Mario NegriPrimary Membranous Nephropathy

Start: 2021-12-17Target: 20Updated: 2024-12-20

Obinutuzumab Treatment in Frequently Relapsing and Rituximab-Dependent Idiopathic Nephrotic Syndrome in Adults: a fully academic, single-arm, open, prospective, intervention trial

Not yet recruitingCTIS2025-523306-33-00

Istituto Di Ricerche Farmacologiche Mario NegriIdiopathic Nephrotic Syndrome

Target: 10Updated: 2026-02-23

Phase 3

A Prospective, double-blind, randomized, single centre trial to evaluate the rate of RAAS inhibitor withdrawal or down-titration in non-dialysis patients with CKD stage IIIB to Vrandomized to Patiromer or placebo

CompletedCTIS2023-503984-41-00

Mario Negri Institute For Pharmacological Research IRCCSHyyperkalemia in CKD stage IIIB to V patients

Start: 2023-08-02End: 2024-10-16Target: 1Updated: 2023-10-17